This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood vascular tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.
This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Keywords: benign childhood vascular tumor; childhood angiofibroma; childhood angiosarcoma; childhood benign vascular tumor of the liver; childhood composite hemangioendothelioma; childhood epithelioid hemangioendothelioma; childhood epithelioid hemangioma; childhood locally aggressive or borderline vascular tumor; childhood malignant vascular tumor; childhood papillary intralymphatic angioendothelioma; childhood pseudomyogenic hemangioendothelioma; childhood pyogenic granuloma; childhood retiform hemangioendothelioma; childhood spindle cell hemangioma; childhood tufted angioma; childhood vascular neoplasm; congenital hemangioma; infantile hemangioma; juvenile nasopharyngeal angiofibroma; Kaposiform hemangioendothelioma; non-involuting congenital hemangioma; partially involuting congenital hemangioma; rapidly involuting congenital hemangioma.